Polaris Capital Management LLC Increases Stake in Gilead Sciences, by 1.5% in Fourth Quarter.

Trending News 🌥️

Gilead Sciences ($NASDAQ:GILD), Inc. is a biopharmaceutical company that focuses on discovering, developing, and commercializing therapeutics for the treatment of life-threatening diseases. In the fourth quarter, Polaris Capital Management LLC increased its stake in Gilead Sciences, Inc. by 1.5%, according to the most recent filing with the Securities and Exchange Commission. This indicates a strong confidence in the company’s strategy and prospects, as well as its market performance. With its increasing shareholding in Gilead Sciences, Polaris Capital Management LLC stands to benefit from the potential growth of the company’s stock price over time.

Analysis

At GoodWhale, we have performed an in-depth analysis of GILEAD SCIENCES‘s financials. After our assessment, we have rated GILEAD SCIENCES as a medium risk investment in terms of financial and business aspects. We have also detected 2 risk warnings in their income sheet and balance sheet. To gain access to a detailed breakdown and explanation of these warnings, you will need to be a registered user of the GoodWhale platform. So if you’re interested in learning more, be sure to register today! More…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Gilead Sciences. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Gilead Sciences. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Gilead Sciences. More…

Key Ratios Snapshot

Some of the financial key ratios for Gilead Sciences are shown below. More…

Peers

In the biopharmaceutical industry, competition is fierce. Among the companies vying for market share are Gilead Sciences Inc, Eli Lilly and Co, Amgen Inc, and SCYNEXIS Inc. All of these companies are working to develop new and innovative treatments for a variety of diseases.

– Eli Lilly and Co ($NYSE:LLY)

Eli Lilly and Co is a pharmaceutical company with a market cap of 316.8 billion as of May 2021. The company has a return on equity of 45.88% and is headquartered in Indianapolis, Indiana. Eli Lilly and Co develops and markets prescription medications and over-the-counter products. The company’s products are available in approximately 120 countries.

– Amgen Inc ($NASDAQ:AMGN)

Amgen Inc is a biopharmaceutical company with a market cap of 135.3B as of 2022. The company has a return on equity of 460.37%. Amgen Inc is a biopharmaceutical company that discovers, develops, manufactures, and delivers human therapeutics worldwide. The company offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and nephrology.

– SCYNEXIS Inc ($NASDAQ:SCYX)

SCYNEXIS Inc. is a biopharmaceutical company, which focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. The company’s lead product, SCY-078, is an oral and intravenous antifungal agent in Phase 3 clinical development for the treatment of serious and life-threatening invasive fungal infections. SCYNEXIS Inc. was founded by Peter R. Lupton, David P. Lupton and George W. Schmidt in December 1997 and is headquartered in Durham, NC.

Summary

The hedge fund increased its stake in Gilead by 1.5%, showing confidence in the company’s performance. This is a sign that investors are continuing to recognize Gilead’s potential for growth and sustainability. With a focus on developing treatments for serious and life-threatening diseases, Gilead has seen a positive reaction from the market and investors. With a history of producing effective treatments, Gilead is an attractive choice for investors looking for a long term investment.